Psoriasis

Following this week's Science of Skin media roundtable hosted by AbbVie, panelist and National Psoriasis Foundations President and CEO Leah Howard, JD, discusses the importance of advocacy and mental health in chronic skin conditions.

Alexandra K. Golant, MD, and Mona Shahriari, MD, share take-home pearls on the management of plaque psoriasis, highlighting the use of topical treatment to simplify the treatment regimen.

Expert dermatologists discuss plaque psoriasis patient populations that may not be ideal candidates for PDE-4 inhibitor treatment, as well as gaps that remain in the plaque psoriasis treatment landscape.

Experts in dermatology comment on the impact of both roflumilast and tapinarof on the treatment of plaque psoriasis.

Mark Lebwohl, MD, discusses the utility of spesolimab, the only FDA-approved treatment for the management of patients with from generalized pustular psoriasis (GPP), highlighting the rapid efficacy of this therapy.

Erin Boh, MD, presents the case of a 60-year-old African American woman with generalized pustular psoriasis (GPP) covering her medical history, initial presentation, potential disease trigger, highlighting important comorbidities of concern and their impact on treatment selection.

This Psoriasis Awareness Month, Dermatology Times is looking back at the treatment and research landscape of 2023.

Jennifer Conner, MPAS, PA-C, and Lakshi Aldredge, MSN, ANP-BC, comment on approaches to escalating treatment of plaque psoriasis from topical therapy to systemic therapy and initiating that conversation with the patient.

Experts in dermatology review a case of a patient with plaque psoriasis concentrated on her hands and discuss taking the patient’s preferences into consideration when selecting treatment.

Five nurse practitioners and physician assistants review patient case presentations and discuss unmet needs in the psoriasis landscape.

Drs Alexandra K. Golant and Mona Shahriari review the efficacy data of roflumilast and tapinarof in the treatment of plaque psoriasis.

Expert dermatologists provide an overview of 2 newer topical treatments in the plaque psoriasis landscape, roflumilast and tapinarof.

Survey responses revealed the rates and times at which patients switched from oral to biologic therapies.

Laura Bush, DMSc, PA-C, and Terry Faleye, MPAS, PA-C, discuss metrics to determine clearance in plaque psoriasis and how the provider’s expectations may be different from the patient’s expectations.

Lakshi Aldredge, MSN, ANP-BC, discusses how speed of treatment response guides treatment selection for the patient, taking patient preference into consideration. Jennifer Conner, MPAS, PA-C, comments on treatment failure in plaque psoriasis.

In subgroups based on age and bodyweight, treatment with secukinumab did not create new safety signals.

This Psoriasis Awareness Month, test your knowledge of the condition. Click here to answer this week's poll.

Alexandra K. Golant, MD, and Mona Shahriari, MD, share thoughts on newer topical treatments as well as the role of topical treatments in managing plaque psoriasis.

Expert dermatologists discuss approaches to treatment selection for patients with plaque psoriasis, taking into account the impact of the therapy on quality of life.

Jennifer Conner, MPAS, PA-C, Terry Faleye, MPAS, PA-C, and Laura Bush, DMSc, PA-C, comment on approaches to treatment selection in managing plaque psoriasis, highlighting topical treatment in combination with other therapies.

Lakshi Aldredge, MSN, ANP-BC, reviews the mechanism of action of deucravacitinib, commenting on its efficacy in the treatment of plaque psoriasis.

Mona Shahriari, MD, comments on plaque psoriasis in skin of color populations, as well as the importance of shared decision-making between patient and dermatologist.

Alexandra K. Golant, MD, and Mona Shahriari, MD, provide an overview of the pathophysiology of plaque psoriasis, commenting on the many comorbidities that stem from this disease.

These findings come from one of the largest related studies to date.

AbbVie announced that patients treated with risankizumab achieved significantly higher results than those given apremilast.